|
|
Volumn 299, Issue 4, 2008, Pages 395-396
|
|
Strides made in red blood cell disorders, but substantial barriers to care remain
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DEFERASIROX;
DEFEROXAMINE;
HYDROXYUREA;
ANTISICKLING AGENT;
BENZOIC ACID DERIVATIVE;
IRON CHELATING AGENT;
TRIAZOLE DERIVATIVE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG SAFETY;
ERYTHROCYTE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
IRON CHELATION;
MEDICAL RESEARCH;
MONOTHERAPY;
PHYSICIAN;
PLASMA HALF LIFE;
PRIORITY JOURNAL;
SHORT SURVEY;
SICKLE CELL ANEMIA;
STROKE;
THALASSEMIA;
UNITED STATES;
BRAIN DISEASE;
CHELATION THERAPY;
HEMATOLOGIC DISEASE;
HEMATOLOGY;
NOTE;
ANEMIA, SICKLE CELL;
ANTISICKLING AGENTS;
BENZOIC ACIDS;
BRAIN DISEASES;
CHELATION THERAPY;
HEMATOLOGIC DISEASES;
HEMATOLOGY;
HUMANS;
HYDROXYUREA;
IRON CHELATING AGENTS;
TRIAZOLES;
|
|
EID: 38749092257
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2008.3 Document Type: Short Survey |
|
Times cited : (3)
|
|
References (0)
|